Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.60%17 Net Debt Paydown Yield % is 0.26% as of Aug. 14, 2026. GuruFocus rates ROCO:7762 with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 919 Drug Manufacturers companies, Pet Pharm Biotech Co ranks better than 64.53% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Pet Pharm Biotech Co's Net Debt Paydown Yield % was 0.26%.
Pet Pharm Biotech Co (ROCO:7762) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Pet Pharm Biotech Co Net Debt Paydown Yield % Related Terms
Pet Pharm Biotech Co Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co Net Debt Paydown Yield % Chart
ROCO:7762 vs LLY, JNJ, ABBV: Net Debt Paydown Yield % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co Net Debt Paydown Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.26% mean?
Pet Pharm Biotech Co (ROCO:7762) has a Net Debt Paydown Yield % of 0.26% as of Aug. 14, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Pet Pharm Biotech Co and its competitors. According to the industry distribution chart, Pet Pharm Biotech Co ranks #326 out of 919 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is Pet Pharm Biotech Co's Net Debt Paydown Yield % too high?
Pet Pharm Biotech Co's current Net Debt Paydown Yield % is 0.26%. Based on the distribution chart, Pet Pharm Biotech Co ranks #326 out of 919 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Net Debt Paydown Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #326 out of 919 companies for Net Debt Paydown Yield %. This puts Pet Pharm Biotech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Drug Manufacturers company?
A good Net Debt Paydown Yield % depends on the Drug Manufacturers industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Net Debt Paydown Yield % is 0.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Net Debt Paydown Yield % of 0.26%. The current Net Debt Paydown Yield % is 0.26%. Pet Pharm Biotech Co's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Net Debt Paydown Yield % is 0.26% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
17GF Score
Get the complete analysis for ROCO:7762
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
